MASS
Company Description
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 56.20M | 59.63M | 50.23M | 46.85M | 42.21M | 26.89M | 17.97M | 22.05M |
| Net Income | (36.64M) | (72.21M) | (36.40M) | (33.56M) | (22.17M) | (12.82M) | (13.37M) | (7.54M) |
| EPS | 0.54 | -2.12 | -1.13 | -1.07 | -0.79 | -2.35 | -2.02 | -0.93 |
| Free Cash Flow | (24.64M) | (30.85M) | (27.10M) | (22.98M) | (29.82M) | 4.12M | (11.40M) | (9.62M) |
| FCF / Share | -0.68 | -0.91 | -0.84 | -0.73 | -1.07 | 0.75 | -1.51 | -1.19 |
| Operating CF | (23.69M) | (30.25M) | (25.06M) | (20.93M) | (29.08M) | 4.13M | (11.00M) | (8.90M) |
| Total Assets | 190.07M | 159.48M | 202.98M | 242.59M | 260.91M | 178.83M | 37.66M | 27.75M |
| Total Debt | 16.71M | 6.61M | 5.95M | 19.51M | 20.85M | 21.86M | 22.79M | 17.93M |
| Cash & Equiv | 112.97M | 44.03M | 121.04M | 188.42M | 224.07M | 159.23M | 17.91M | 7.07M |
| Book Value | 143.70M | 114.59M | 165.49M | 190.60M | 214.60M | 139.04M | (63.17M) | (50.18M) |
| Return on Equity | -0.25 | -0.63 | -0.22 | -0.18 | -0.10 | -0.09 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.38M | 17.38M | 14.01M | 13.04M | 11.78M | 18.82M | 14.52M | 11.46M | 7.42M | 14.35M | 14.30M | 12.09M |
| Net Income | (11.96M) | 4.28M | (14.91M) | (13.31M) | 43.60M | (19.45M) | (29.30M) | (12.55M) | (10.92M) | (7.43M) | (7.09M) | (9.35M) |
| EPS | -0.32 | 0.12 | -0.41 | -0.37 | 1.23 | -0.57 | -0.84 | -0.37 | -0.33 | -0.23 | -0.22 | -0.29 |
| Free Cash Flow | 1.04M | 1.32M | (4.88M) | (5.91M) | (15.18M) | (2.43M) | (5.76M) | (12.39M) | (10.26M) | (2.26M) | (4.81M) | (8.20M) |
| FCF / Share | 0.03 | 0.04 | -0.14 | -0.16 | -0.43 | -0.07 | -0.17 | -0.36 | -0.31 | -0.07 | -0.15 | -0.25 |
| Operating CF | 1.08M | 1.32M | (4.20M) | (5.78M) | (15.02M) | (2.24M) | (5.61M) | (13.04M) | (9.36M) | (1.93M) | (4.60M) | (7.88M) |
| Total Assets | 186.69M | 190.07M | 190.87M | 191.70M | 196.03M | 159.48M | 178.28M | 208.77M | 189.79M | 202.98M | 208.47M | 210.83M |
| Total Debt | 4.47M | 4.63M | 4.35M | 4.43M | 3.77M | 6.61M | 7.18M | 5.59M | 5.46M | 5.95M | 6.40M | 6.82M |
| Cash & Equiv | 67.56M | 70.52M | 62.80M | 61.75M | 79.16M | 44.03M | 45.02M | 46.81M | 104.60M | 121.04M | 118.21M | 133.00M |
| Book Value | 134.17M | 143.70M | 136.30M | 148.82M | 159.42M | 114.59M | 131.04M | 156.36M | 156.89M | 165.49M | 169.93M | 174.46M |
| Return on Equity | -0.09 | 0.03 | -0.11 | -0.09 | 0.27 | -0.17 | -0.22 | -0.08 | -0.07 | -0.04 | -0.04 | -0.05 |
